{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:16:51Z","timestamp":1791227811543,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Brain Research"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.molbrainres.2005.01.012","type":"journal-article","created":{"date-parts":[[2005,2,27]],"date-time":"2005-02-27T00:44:46Z","timestamp":1109465086000},"page":"103-108","source":"Crossref","is-referenced-by-count":80,"title":["Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease"],"prefix":"10.1016","volume":"134","author":[{"given":"Mika","family":"Shimoji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen S.","family":"Mandir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valina L.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted M.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molbrainres.2005.01.012_bib1","first-page":"879","article-title":"Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies","volume":"152","author":"Baba","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.35.7.949","article-title":"Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases","volume":"35","author":"Ballard","year":"1985","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.molbrainres.2005.01.012_bib3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","article-title":"Chronic systemic pesticide exposure reproduces features of Parkinson's disease","volume":"3","author":"Betarbet","year":"2000","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0304-3940(99)00208-6","article-title":"Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry","volume":"265","author":"Braak","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib5","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1073\/pnas.80.14.4546","article-title":"A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"80","author":"Burns","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib6","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJM198505303122203","article-title":"The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"312","author":"Burns","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0166-2236(97)01213-7","article-title":"The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease","volume":"21","author":"Clayton","year":"1998","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1073\/pnas.97.2.571","article-title":"Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy","volume":"97","author":"Conway","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.molbrainres.2005.01.012_bib10","doi-asserted-by":"crossref","first-page":"14524","DOI":"10.1073\/pnas.172514599","article-title":"Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP","volume":"99","author":"Dauer","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0896-6273(02)00780-8","article-title":"Animal models of PD: pieces of the same puzzle?","volume":"35","author":"Dawson","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.molbrainres.2005.01.012_bib12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ana.410350107","article-title":"Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease","volume":"35","author":"Dexter","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib13","doi-asserted-by":"crossref","first-page":"A32","DOI":"10.1038\/19899","article-title":"Prospects for new restorative and neuroprotective treatments in Parkinson's disease","volume":"399","author":"Dunnet","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.molbrainres.2005.01.012_bib14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0306-4522(86)90102-8","article-title":"Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys","volume":"18","author":"Eidelberg","year":"1986","journal-title":"Neuroscience"},{"key":"10.1016\/j.molbrainres.2005.01.012_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1006\/jsbi.2000.4262","article-title":"Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins","volume":"130","author":"El-Agnaf","year":"2000","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/8820","article-title":"Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions","volume":"22","author":"Engelender","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib17","first-page":"600","article-title":"Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Neuropathologic considerations","volume":"60","author":"Forno","year":"1993","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib18","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.290.5493.985","article-title":"Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions","volume":"290","author":"Giasson","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.molbrainres.2005.01.012_bib19","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/70918","article-title":"NOS knockouts and neuroprotection","volume":"5","author":"Grunewald","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/311467a0","article-title":"Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors","volume":"311","author":"Heikkila","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.molbrainres.2005.01.012_bib21","first-page":"24","article-title":"Oxidative mechanisms in nigral cell death in Parkinson's disease","volume":"13","author":"Jenner","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib22","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1002\/ana.410440712","article-title":"Understanding cell death in Parkinson's disease","volume":"44","author":"Jenner","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.ne.11.030188.000501","article-title":"MPTP toxicity: implications for research in Parkinson's disease","volume":"11","author":"Kopin","year":"1988","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib24","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1212\/WNL.47.6_Suppl_3.153S","article-title":"The etiology of Parkinson's disease with emphasis on the MPTP story","volume":"47","author":"Langston","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.molbrainres.2005.01.012_bib25","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.molbrainres.2005.01.012_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0306-3623(90)90898-V","article-title":"Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice","volume":"21","author":"Lau","year":"1990","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib27","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/70978","article-title":"Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease","volume":"5","author":"Liberatore","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib28","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1073\/pnas.96.10.5774","article-title":"Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism","volume":"96","author":"Mandir","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/311464a0","article-title":"Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism","volume":"311","author":"Markey","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.molbrainres.2005.01.012_bib30","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in a-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.molbrainres.2005.01.012_bib31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ana.20186","article-title":"Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease","volume":"56","author":"McNaught","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0006-8993(02)03514-X","article-title":"Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease","volume":"956","author":"Meredith","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib33","first-page":"282","article-title":"Mitochondrial energy crisis in Parkinson's disease","volume":"60","author":"Mizuno","year":"1993","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib34","doi-asserted-by":"crossref","first-page":"27230","DOI":"10.1074\/jbc.M212436200","article-title":"Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications","volume":"278","author":"Norris","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib35","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0306-4522(01)00295-0","article-title":"Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP\/probenecid treatment","volume":"106","author":"Petroske","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.molbrainres.2005.01.012_bib36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00005072-199305000-00001","article-title":"Pathology and biology of the Lewy body","volume":"52","author":"Pollanen","year":"1993","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib37","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1073\/pnas.93.10.4565","article-title":"Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity","volume":"93","author":"Przedborski","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib38","first-page":"161","article-title":"Neurotoxicity and the mechanisms of cell death in Parkinson's disease","volume":"69","author":"Schapira","year":"1996","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib39","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/sj.cdd.4400432","article-title":"Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia","volume":"5","author":"Trojanowski","year":"1998","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib40","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1471-4159.2000.740721.x","article-title":"Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP","volume":"74","author":"Vila","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/1531-8249(200004)47:4<521::AID-ANA18>3.0.CO;2-B","article-title":"Synphilin-1 is present in Lewy bodies in Parkinson's disease","volume":"47","author":"Wakabayashi","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molbrainres.2005.01.012_bib42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s004010050918","article-title":"Accumulation of alpha-synuclein\/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy","volume":"96","author":"Wakabayashi","year":"1998","journal-title":"Acta Neuropathol. (Berl.)"}],"container-title":["Molecular Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169328X05000367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169328X05000367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T12:28:46Z","timestamp":1548678526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169328X05000367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0169328X05000367"],"URL":"https:\/\/doi.org\/10.1016\/j.molbrainres.2005.01.012","relation":{},"ISSN":["0169-328X"],"issn-type":[{"value":"0169-328X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}